All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Vogel Provides Insights on Advanced HCC Management and Expanding Immunotherapy Combinations

March 11th 2024

Arndt Vogel, MD, discusses the importance of multidisciplinary tumor boards in navigating the treatment arsenal in advanced hepatocellular carcinoma.

Community/Academic Research Collaboration Paves the Way for Improved Cancer Care

March 11th 2024

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss the ins and outs of clinical trial partnerships between community and academic cancer centers.

2023 Fox Chase Cancer Center Annual Report: We Advance Together

March 11th 2024

It is often said that one person can make a difference, but it is also evident that when we band together, we can achieve greatness.

European Medicines Agency Grants Orphan Drug Designation to Tinengotinib for Biliary Tract Cancer

March 11th 2024

Tinengotinib has been awarded orphan drug designation from the European Medicines Agency for use in select patients with biliary tract cancer.

FDA Lifts Partial Clinical Hold on Trial Evaluating NX-2127 in R/R B-Cell Malignancies

March 11th 2024

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Evolving With the Times

March 11th 2024

Jill Gilbert, MD, explains how publications must evolve to utilize modern educational platforms to reach readers.

Neoadjuvant Immunotherapy is Helping Redefine Resectability in NSCLC

March 11th 2024

Neel P. Chudgar, MD, discusses the nuances of defining resectability in patients with non–small cell lung cancer.

Dr Shore on Key Clinical Trial Data in Biochemically Recurrent Prostate Cancer

March 11th 2024

Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.

Dr Hussain on Key Ongoing Clinical Trials in Metastatic Castrate-Resistant Prostate Cancer

March 11th 2024

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

MRD Testing Presents Challenges and Opportunities in Breast Cancer Care

March 10th 2024

Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive.

Dr Bochner on Key Points for Community Oncologists in the Management of Muscle-Invasive Bladder Cancer

March 10th 2024

Bernard H. Bochner, MD, FACS, discusses considerations for community oncologists when treating patients with muscle-invasive bladder cancer.

Dr Xu on Treatment Sequencing Considerations in Metastatic Renal Cell Carcinoma

March 10th 2024

Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.

HER2-Directed Therapies Continue to Shape Improved Breast Cancer Outcomes

March 10th 2024

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

Artificial Intelligence in Prostate Cancer Pathology: Friend or Foe?

March 9th 2024

Peter A. Humphrey, MD, PhD, presents on the standing of artificial intelligence in prostate cancer pathology.

Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena

March 9th 2024

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

FDA's MIDAC Votes in Support of Benefit-Risk Profile of Lumisight Optical Imaging Agent for Breast Cancer Detection

March 9th 2024

The FDA's Medical Imaging Drugs Advisory Committee voted 16 to 2 in support of the benefit-risk profile of Lumisight.

Piecing the Puzzle Together: Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer

March 9th 2024

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

Dr Tagawa on the Role of PARP Inhibitors in Prostate Cancer Treatment

March 9th 2024

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the standing of PARP inhibitors in the treatment paradigm of metastatic castration-resistant prostate cancer.

Dr Dreicer on Improving Clinical Trial Design in Prostate Cancer

March 9th 2024

Robert Dreicer, MD, discusses the shortcomings of current clinical trials in prostate cancer and what he sees as the biggest area of improvement.

Neoadjuvant Chemotherapy Has Led to De-Escalation of Breast Cancer Surgery and Radiation

March 8th 2024

Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.